Translumina Therapeutics, known for its drug-eluting stents, has made a strategic investment in the UAE, marking a significant milestone in its global expansion. The company's partnership with the German Heart Centre and recent acquisitions have strengthened its product offerings.
 |
| Translumina Therapeutics has made a strategic investment in the UAE, marking a significant milestone in its global expansion. The company's innovative products and strong partnerships position it as a key player in the MENA region. Image Courtesy: Nancy Chugh |
New Delhi, India – September 21, 2024:
India's leading coronary stent manufacturer, Translumina Therapeutics, has taken a significant stride towards its global expansion by establishing a direct presence in the United Arab Emirates (UAE). This strategic move positions the company to capitalize on the growing healthcare market in the Middle East and North Africa (MENA) region.
Translumina, renowned for its innovative drug-eluting stent technologies, has been making waves in the international market. The company's partnership with the prestigious German Heart Centre has led to the development of groundbreaking medical devices, including the world's longest-studied DES. This collaboration has solidified Translumina's reputation as a pioneer in the field of interventional cardiology.
The UAE, with its thriving economy and world-class healthcare infrastructure, offers a fertile ground for Translumina's expansion. By establishing a direct presence in the region, the company can better serve local patients and healthcare providers, while also leveraging the UAE as a gateway to other MENA markets.
Translumina's recent acquisitions of Blue Medical and Lamed have further strengthened its product portfolio, offering a comprehensive range of vascular surgery solutions. This strategic move positions the company as a leading player in the global medical device market. The acquisition of Blue Medical, a Dutch medical device company specializing in drug-coated balloons, has expanded Translumina's offerings beyond stents, while the acquisition of Lamed, a German vascular surgery market leader, has strengthened the company's presence in Europe.
"This expansion into the UAE is a testament to our dedication to making India a global hub for medical devices," said Gurmit Singh Chugh, Co-Founder and Chairman of Translumina. "We believe that our advanced technology and commitment to quality will make a significant impact in the MENA region."
The UAE's strategic location and business-friendly environment make it an ideal hub for Translumina's operations. The company's presence in the region will enable it to better understand local market dynamics, build strong relationships with healthcare providers, and respond effectively to the specific needs of patients in the MENA region.
As Translumina continues to expand its operations, the company remains committed to providing innovative and affordable healthcare solutions to patients around the world. The UAE expansion is a significant milestone in the company's journey towards global dominance, and it is poised to make a lasting impact on the healthcare landscape in the MENA region.